Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response Biomedical, Roche to take CV tests to North America

This article was originally published in Clinica

Executive Summary

Roche Diagnostics is set to take Response Biomedical’s line of cardiovascular point-of-care tests to the North American market. The two firms have entered an exclusive agreement that will see Roche make Response’s RAMP 200 (rapid analyte measurement platform) tests for Troponin-I, CK-MB, Myoglobin and NT-proBNP available in the US, Canadian and other unnamed markets. According to Roche, the RAMP tests provide physicians with what it calls improved “vein-to-brain” time, allowing faster treatment times. Roche had previously gained worldwide rights to the line in June for an undisclosed fee. Financial details of this deal were also not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel